GT Biopharma, Inc. (GTBP) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Company: GT Biopharma, Inc.
Reporting Period: Quarter and six months ended June 30, 2024.
Business Model: Clinical-stage biopharmaceutical company developing immune-oncology products using proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® platforms. The company has no approved products and generates no revenue.
Operational Update: As of July 1, 2024, the company became fully remote. In late June 2024, the FDA cleared the Investigational New Drug (IND) application for GTB-3650, with patient enrollment anticipated in the second half of 2024.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $0 |
| Net Loss | $(5,976) |
| Net Loss Per Share (Basic & Diluted) | $(3.86) |
| Cash and Cash Equivalents | $9,249 |
| Short-term Investments | $0 |
| Total Current Assets | $9,267 |
| Total Current Liabilities | $3,759 |
| Working Capital | $5,508 |
| Stockholders' Equity | $5,508 |
| Net Cash Used in Operating Activities | $(7,699) |
| Net Cash Provided by Financing Activities | $2,976 |
Material Changes vs. Prior Period
- Net Loss: Net loss increased by $3.76 million (169%) compared to the six months ended June 30, 2023. This increase was primarily driven by a $3.54 million decrease in the gain from the change in fair value of warrant liability and a $547,000 decrease in gain on extinguishment of debt.
- Operating Expenses: Total operating expenses decreased slightly by $289,000 (4%) to $7.0 million. Research and Development (R&D) expenses decreased by $1.19 million (32%), while Selling, General, and Administrative (SG&A) expenses increased by $1.58 million (60%) due to higher legal and professional fees.
- Liquidity Position: Cash and cash equivalents increased to $9.2 million from $1.1 million at year-end 2023, driven by the sale of $12.9 million in short-term investments and $3.0 million in proceeds from a registered direct offering in May 2024.
- Warrant Liability: The fair value of warrant liability decreased to $277,000 from $1.05 million at December 31, 2023, resulting in a $775,000 gain in the current period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management believes existing cash resources are insufficient to fund operations for one year from the filing date without additional financing. Failure to secure funding could force delays or elimination of discretionary spending.
- Outlook: The company anticipates advancing GTB-3650 into clinical trials in H2 2024 and filing an IND for GTB-5550 in H1 2025. Direct clinical and preclinical expenses are expected to increase in the second half of 2024.
- Legal Proceedings:
- Ohri Matter: Arbitration filed against former CFO Manu Ohri for breach of fiduciary duties and contract; response due August 20, 2024.
- Berk Matter: Lawsuit by former interim CEO Dr. Gregory Berk alleging SOX retaliation; company believes claim is without merit.
- TWF Global Matter: Dispute regarding convertible notes and share registration; company filed for interpleader in New York.
- Handelman Matter: Arbitration against former CFO Michael Handelman concluded in May 2024 with a final award in the company's favor ($473,000 legal fees + return of shares).
- Unusual Items: The company issued 127,597 shares of common stock valued at $810,000 to settle vendor payables (Cytovance) during the period.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $9.2 million cash balance against projected burn rates given the "Going Concern" warning.
- Financing Needs: Assess the likelihood and terms of securing additional capital to fund the anticipated increase in clinical trial costs for GTB-3650.
- Legal Exposure: Monitor the status of the Ohri and Berk litigation matters for potential financial impact or management distraction.
- Related Party Transactions: Review the ongoing settlement of accounts payable with Cytovance Biologics (a related party owning >5% of stock) via cash and stock issuances.
- Warrant Liability Volatility: Understand how future stock price fluctuations will impact the fair value of the remaining $277,000 warrant liability and net income.